China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, ...

"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Haleon partners with Indian Dental Association to inaugurate the first D20 International Symposium: Our Bureau, Mumbai Wednesday, July 30, 2025, 15:30 Hrs [IST] Haleon (erstwhile ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

"Uveal Melanoma Market Insight, Epidemiology and Market Forecast - 2034"The uveal melanoma treatment market is experiencing ...

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.

GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...